查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080397

鎮痛藥市場：2026-2032年全球市場預測（依藥物類型、給藥途徑、處方狀態、年齡層、適應症及通路分類）

Analgesics Market by Type of Drug, Route of Administration, Prescription Status, Age Group, Indication, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，止痛藥市場規模將達到 718.2 億美元，複合年成長率為 6.91%。

主要市場統計數據
基準年 2025 449.6億美元
預計年份：2026年 479.9億美元
預測年份 2032 718.2億美元
複合年成長率 (%) 6.91%

疼痛藥物仍然是最重要的藥物類別之一，因為它是人們尋求醫療保健的主要原因之一，也是導致殘疾、生產力下降和醫療保健服務取得困難的重要因素。此類別包括非鴉片類鎮痛藥，例如對乙醯胺酚/乙醯胺酚和非類固醇消炎劑（NSAIDs），鴉片類鎮痛藥，局部鎮痛藥，固定劑量複方組合藥物，以及用於治療神經病變疼痛、發炎性疼痛、癌症相關疼痛和術後疼痛的輔助性治療。

推動需求成長的因素包括人口老化、肌肉骨骼疾病盛行率上升、癌症相關疼痛、術後復原需求以及消費者對非處方止痛藥日益成長的依賴。同時，包括美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 在內的監管機構，透過降低鴉片類藥物風險、加強藥物安全監測要求、發布對乙醯胺酚肝毒性警告以及傳播非類固醇抗發炎藥 (NSAIDs) 心血管、腎臟和消化器官系統風險安全資訊等措施，持續影響該領域的發展趨勢。

止痛藥市場發生變革性變化

鎮痛領域正在經歷一場變革，從以高劑量為優先的處方模式轉向基於實證醫學、風險分層的疼痛管理。醫療保健系統正在優先考慮多方面的疼痛護理、最大限度減少鴉片類藥物使用的方案、濫用預防製劑、處方藥監測以及加強患者教育，以在有效緩解疼痛和確保安全之間取得平衡。

人工智慧對止痛藥領域的累積影響

人工智慧 (AI) 正在對整個鎮痛價值鏈產生累積影響，從標靶發現和分子篩檢到實際安全性監測。 AI 平台可以分析基因組學、蛋白質組學、臨床、影像學和理賠數據，以識別疼痛路徑、對患者進行分層，並加速開發用於治療發炎性疼痛、神經病變疼痛和術後疼痛的非鴉片類候選藥物。

關於止痛藥的關​​鍵區域性見解

由於人口老化、慢性疼痛疾病診斷率上升、醫療保健覆蓋範圍擴大，以及中國和印度強大的學名藥生產能力，亞太地區的戰略重要性日益凸顯。日本和韓國透過先進的疼痛診所、較高的預期壽命和完善的保險報銷體系來滿足需求，而澳洲則透過其國家監管機構維持嚴格的藥品分類和安全資訊提供系統。在東南亞，隨著藥局現代化和基本藥物政策的推進，獲得價格合理的止痛藥的機會也不斷改善。

關於止痛藥的關​​鍵群體特定見解

在東協地區，都市區醫療保健服務的普及、藥房現代化、非處方藥使用量的增加，以及為提高產品品質和促進跨境市場准入而協調監管的努力，都促進了鎮痛藥的廣泛使用。在海灣合作理事會（GCC）國家，對醫療保健領域的大量投資、醫院擴建、集中採購以及數位醫療項目的推進，在日益規範的法律規範下，為品牌鎮痛藥、專科鎮痛藥和醫院處方鎮痛藥創造了新的機遇。

主要國家止痛藥使用趨勢

美國的特點是鎮痛藥使用率高、鴉片類藥物風險管理積極主動、處方藥監測到位，以及對非鴉片類替代藥物的強勁需求。加拿大同樣重視安全，並已建立省級報銷機制和監測計畫。同時，墨西哥的非處方藥市場正在成長，同時對價格合理的學名藥的需求也在增加，藥局的可及性也在提高。在巴西，鎮痛藥市場的發展得益於私人藥局網路、公共採購、基本藥物政策以及學名藥在龐大而多元化的醫療保健系統中的廣泛應用。

為疼痛緩解行業的領導者提供的實用建議

產業領導者應優先考慮非鴉片類藥物的創新、以安全為中心的生命週期管理，以及提供能夠證明其具有臨床意義的鎮痛效果、減少不利事件和提高患者依從性的證據。投資外用製劑、緩釋製劑、防濫用製劑、兒童製劑、老年人適用製劑和複方製劑，將有助於製造商在競爭激烈的學名藥和非處方藥市場中脫穎而出。

鎮痛藥物分析的調查方法

本執行摘要基於系統的調查方法，結合了二手研究、產業一手檢驗和分析三角驗證。資訊來源包括公共衛生機構、監管機構、臨床指南、藥物安全監測資訊、同行評審文獻、行業數據、基本藥物清單、保險報銷標準和經認證的醫療保健資料庫。

結論：止痛藥的未來

止痛藥市場至關重要且具韌性，其發展日益受到安全性、可近性和創新性的影響。雖然非處方學名藥有助於擴大患者群體，但鴉片類藥物的合理使用、非類固醇抗發炎藥的安全隱患以及對乙醯胺酚的非類固醇消炎劑風險，都要求嚴格的產品管控、負責任的推廣和透明的溝通。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：止痛藥市場：依藥物類型分類

  • 非鴉片類藥物
    • 乙醯胺酚
    • 非類固醇消炎劑
    • 基於水楊酸鹽的藥物
  • 鴉片類藥物
    • 可待因
    • Fentanyl
    • 氫可酮
    • 氫可酮
    • 羥考酮

第8章：止痛藥市場：依給藥途徑分類

  • 肌肉內部
  • 靜脈注射（IV）
  • 口服
    • 膠囊
    • 藥片
  • 直腸
  • 外用
  • 經皮給藥

第9章：止痛藥市場：依處方狀態分類

  • 非處方藥
  • 處方

第10章：止痛藥市場：依年齡層別分類

  • 兒童
  • 成人
  • 老年人

第11章：鎮痛藥市場：依適應症分類

  • 急性疼痛
    • 與創傷相關的疼痛
    • 術後疼痛
  • 慢性疼痛
    • 關節炎
    • 腰痛
    • 癌症疼痛
    • 神經病變疼痛

第12章：止痛藥市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：止痛藥市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 鎮痛藥市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 鎮痛藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • Alembic Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals LLC
  • Apotex Inc.
  • Assertio Holdings, Inc.
  • AstraZeneca PLC
  • Averitas Pharma, Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Cipla Limited
  • Collegium Pharmaceutical, Inc.
  • CSPC Pharmaceutical Group
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Grunenthal GmbH
  • Haleon plc
  • Heron Therapeutics, Inc.
  • Hikma Pharmaceuticals plc
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Mallinckrodt plc
  • Merck KGaA
  • Novartis AG
  • Pacira BioSciences, Inc.
  • Perrigo Company plc
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-434CCDA05184

The Analgesics Market is projected to grow by USD 71.82 billion at a CAGR of 6.91% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 44.96 billion
Estimated Year [2026] USD 47.99 billion
Forecast Year [2032] USD 71.82 billion
CAGR (%) 6.91%

Analgesics remain one of the most essential pharmaceutical categories because pain is among the leading reasons people seek medical care and a major driver of disability, productivity loss, and healthcare utilization. The category spans non-opioid analgesics such as acetaminophen/paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs), opioid analgesics, topical pain relievers, fixed-dose combinations, and adjuvant therapies used in neuropathic, inflammatory, cancer-related, and postoperative pain.

Demand is supported by population aging, the rising prevalence of musculoskeletal disorders, cancer-related pain, postsurgical recovery needs, and greater consumer reliance on over-the-counter pain management. At the same time, regulatory agencies, including the U.S. FDA and European Medicines Agency, continue to shape the category through opioid risk mitigation, pharmacovigilance requirements, acetaminophen hepatotoxicity warnings, and safety communications on NSAID cardiovascular, renal, and gastrointestinal risks.

Transformative Shifts in the Analgesics Landscape

The analgesics landscape is being reshaped by the shift from volume-led prescribing to evidence-based, risk-stratified pain management. Health systems are prioritizing multimodal pain care, opioid-sparing protocols, abuse-deterrent formulations, prescription drug monitoring, and stronger patient education to balance effective relief with safety.

Another major shift is the expansion of consumer-centric pain management. Digital pharmacies, e-commerce OTC channels, telehealth consultations, and private-label analgesics are changing how patients access common pain medications. Meanwhile, manufacturers are investing in differentiated delivery formats, including topical gels, transdermal systems, extended-release products, unit-dose packaging, and combination therapies that improve convenience, adherence, dosing accuracy, and targeted pain relief.

Cumulative Impact of Artificial Intelligence on Analgesics

Artificial intelligence is having a cumulative impact across the analgesics value chain, from target discovery and molecule screening to real-world safety monitoring. AI-enabled platforms can analyze genomic, proteomic, clinical, imaging, and claims data to identify pain pathways, stratify patients, and support faster development of non-opioid candidates for inflammatory, neuropathic, and postoperative pain.

In commercial and clinical settings, AI is improving supply planning, adverse-event signal detection, medication adherence programs, and prescribing decision support. For opioids and controlled analgesics, machine learning models are increasingly used to identify patterns associated with misuse, diversion, high-risk prescribing, duplicate therapy, and drug interactions, supporting safer pain management when governed by validated data, transparent algorithms, human oversight, and strong privacy controls.

Key Regional Insights for Analgesics

Asia-Pacific is expanding in strategic importance due to aging populations, higher diagnosis of chronic pain conditions, broader healthcare access, and strong generic manufacturing capacity in China and India. Japan and South Korea support demand through advanced pain clinics, high life expectancy, and established reimbursement systems, while Australia maintains stringent medicine scheduling and safety communications through national regulators. Across Southeast Asia, pharmacy modernization and essential-medicine policies continue to improve access to affordable analgesics.

North America remains a highly mature analgesics environment shaped by established OTC consumption, advanced specialty pain care, and strict opioid stewardship. The United States continues to be influenced by CDC opioid prescribing guidance, FDA risk evaluation and mitigation strategies, prescription drug monitoring programs, and a strong movement toward non-opioid and multimodal approaches, while Canada emphasizes prescription monitoring, harm-reduction policies, and access to evidence-based pain care.

Latin America shows growing demand for affordable analgesics, particularly in Brazil and Mexico, but performance is influenced by healthcare access gaps, currency volatility, informal out-of-pocket spending, and public-sector procurement dynamics. Europe is characterized by robust pharmacovigilance, reimbursement discipline, and regulatory oversight under national agencies and the European Medicines Agency, with Germany, France, Italy, Spain, and the United Kingdom emphasizing safe opioid use, generic penetration, and clinical guideline alignment.

The Middle East, especially GCC countries, is investing in hospital capacity, specialty care, regulated pharmacy channels, and e-prescribing infrastructure, which supports more formalized pain management pathways. Africa continues to face significant unmet need for pain relief and palliative care due to access, affordability, supply continuity, and controlled-medicine availability constraints documented by global health agencies, making essential analgesic availability a persistent public health priority.

Key Group Insights for Analgesics

Within ASEAN, analgesics adoption is supported by expanding urban healthcare access, pharmacy modernization, rising OTC utilization, and regulatory harmonization efforts that improve product quality and cross-border market entry. The GCC benefits from high healthcare investment, hospital expansion, centralized procurement, and digital health programs, creating opportunities for branded, specialty, and hospital-administered analgesics under increasingly structured regulatory oversight.

The European Union remains a quality- and safety-driven environment where pharmacovigilance, centralized and national regulatory procedures, health technology assessment, and pricing discipline influence analgesic adoption. BRICS economies are important because Brazil, Russia, India, China, and South Africa combine large patient pools with domestic manufacturing capabilities, pricing controls, essential-medicine policies, and public health priorities that favor affordable generics and reliable supply.

G7 markets lead in clinical guidelines, safety monitoring, innovation funding, regulatory science, and real-world evidence generation, making them pivotal for non-opioid analgesic development and responsible post-market surveillance. NATO member countries add a distinct demand dimension through military medicine, trauma care, rehabilitation, emergency preparedness, and supply resilience planning for essential pain management therapies used in civilian and defense healthcare systems.

Key Country Insights for Analgesics

The United States is defined by high analgesic utilization, active opioid risk controls, prescription drug monitoring, and strong demand for non-opioid alternatives. Canada follows similar safety priorities with provincial reimbursement dynamics and monitoring programs, while Mexico combines OTC growth with affordability-driven generic demand and expanding pharmacy access. Brazil supports analgesics through private pharmacy networks, public procurement, essential-medicine policies, and strong generic uptake across a large and diverse healthcare system.

In Europe, the United Kingdom emphasizes clinical guidance, cost-effective prescribing, and opioid stewardship, while Germany benefits from advanced reimbursement structures, strong pharmacy access, and established pharmacovigilance. France maintains strict medicine oversight and public reimbursement, Italy and Spain show consistent demand tied to aging populations and musculoskeletal conditions, and Russia remains a large market shaped by domestic production priorities, controlled pricing policies, and changing import dynamics.

China and India are central to access and global supply, with China expanding healthcare coverage, hospital capacity, and domestic innovation while India maintains a major role in generic active pharmaceutical ingredients and finished dosage forms. Japan has sustained analgesic demand from a super-aged population and advanced clinical pathways, Australia emphasizes strict scheduling, poison information, and consumer safety, and South Korea combines advanced healthcare infrastructure with rapid uptake of differentiated pain management products and digital health tools.

Actionable Recommendations for Analgesics Leaders

Industry leaders should prioritize non-opioid innovation, safety-focused lifecycle management, and evidence generation that demonstrates clinically meaningful pain relief, lower adverse-event burden, and improved patient adherence. Investment in topical, extended-release, abuse-deterrent, pediatric-appropriate, geriatric-friendly, and combination formulations can help manufacturers differentiate in crowded generic and OTC segments.

Organizations should strengthen pharmacovigilance, real-world evidence capabilities, and regulatory intelligence to respond quickly to safety signals, label changes, scheduling decisions, and reimbursement expectations. Commercial teams should tailor strategies by channel, with medical education for prescription analgesics, consumer trust-building for OTC brands, responsible claims management, and digital pharmacy partnerships where regulation permits.

Supply resilience is also critical. Leaders should diversify API sourcing, qualify multiple manufacturing sites, monitor controlled-substance compliance, strengthen serialization and anti-counterfeit controls, and maintain transparent quality systems to reduce disruption risk in essential pain medicines.

Research Methodology for Analgesics Analysis

This executive summary is based on a structured research methodology that combines secondary research, primary industry validation, and analytical triangulation. Sources include public health agencies, regulatory authorities, clinical guidelines, pharmacovigilance communications, peer-reviewed literature, trade data, essential-medicine lists, reimbursement references, and recognized healthcare databases.

The analysis evaluates analgesics by product class, route of administration, prescription status, end user, distribution channel, region, economic bloc, and priority country. Findings are validated through cross-source comparison and interpreted using market drivers, restraints, regulatory shifts, supply chain indicators, safety signals, and demand-side healthcare trends to ensure data-backed and decision-ready insight while avoiding unsupported estimates, sizing, share, or forecasting claims.

Conclusion: The Future of Analgesics

The analgesics market is essential, resilient, and increasingly shaped by safety, access, and innovation. While OTC demand and generic availability support broad patient reach, opioid stewardship, NSAID safety concerns, and acetaminophen toxicity risks require disciplined product management, responsible promotion, and transparent communication.

Future leadership will favor organizations that combine clinically differentiated pain relief with strong compliance, responsible commercialization, AI-enabled evidence generation, and region-specific access strategies. As healthcare systems continue moving toward multimodal and personalized pain management, analgesics manufacturers that align efficacy, safety, affordability, and supply reliability will be best positioned to meet patient and provider needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Analgesics Market, by Type of Drug

  • 7.1. Non-Opioids
    • 7.1.1. Acetaminophen
    • 7.1.2. Non-Steroidal Anti-Inflammatory Drugs
    • 7.1.3. Salicylates
  • 7.2. Opioids
    • 7.2.1. Codeine
    • 7.2.2. Fentanyl
    • 7.2.3. Hydrocodone
    • 7.2.4. Morphine
    • 7.2.5. Oxycodone

8. Analgesics Market, by Route of Administration

  • 8.1. Intramuscular
  • 8.2. Intravenous (IV)
  • 8.3. Oral
    • 8.3.1. Capsules
    • 8.3.2. Tablets
  • 8.4. Rectal
  • 8.5. Topical
  • 8.6. Transdermal

9. Analgesics Market, by Prescription Status

  • 9.1. Over-The-Counter
  • 9.2. Prescription

10. Analgesics Market, by Age Group

  • 10.1. Pediatric
  • 10.2. Adult
  • 10.3. Geriatric

11. Analgesics Market, by Indication

  • 11.1. Acute Pain
    • 11.1.1. Injury-related pain
    • 11.1.2. Postoperative pain
  • 11.2. Chronic Pain
    • 11.2.1. Arthritis
    • 11.2.2. Back pain
    • 11.2.3. Cancer pain
    • 11.2.4. Neuropathic pain

12. Analgesics Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Analgesics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Analgesics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Analgesics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. AbbVie Inc.
  • 17.3. Alembic Pharmaceuticals Ltd.
  • 17.4. Amneal Pharmaceuticals LLC
  • 17.5. Apotex Inc.
  • 17.6. Assertio Holdings, Inc.
  • 17.7. AstraZeneca PLC
  • 17.8. Averitas Pharma, Inc.
  • 17.9. Bausch Health Companies Inc.
  • 17.10. Bayer AG
  • 17.11. Bristol-Myers Squibb Company
  • 17.12. C.H. Boehringer Sohn AG & Co. KG
  • 17.13. Cipla Limited
  • 17.14. Collegium Pharmaceutical, Inc.
  • 17.15. CSPC Pharmaceutical Group
  • 17.16. Dr. Reddy's Laboratories Ltd.
  • 17.17. Eli Lilly and Company
  • 17.18. Endo International plc
  • 17.19. F. Hoffmann-La Roche Ltd.
  • 17.20. GlaxoSmithKline plc
  • 17.21. Grunenthal GmbH
  • 17.22. Haleon plc
  • 17.23. Heron Therapeutics, Inc.
  • 17.24. Hikma Pharmaceuticals plc
  • 17.25. Johnson & Johnson Services, Inc.
  • 17.26. Lupin Limited
  • 17.27. Mallinckrodt plc
  • 17.28. Merck KGaA
  • 17.29. Novartis AG
  • 17.30. Pacira BioSciences, Inc.
  • 17.31. Perrigo Company plc
  • 17.32. Pfizer Inc.
  • 17.33. Sanofi S.A.
  • 17.34. Sun Pharmaceutical Industries Limited
  • 17.35. Teva Pharmaceutical Industries Ltd.
  • 17.36. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANALGESICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANALGESICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANALGESICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANALGESICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANALGESICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ANALGESICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANALGESICS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANALGESICS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANALGESICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANALGESICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANALGESICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ANALGESICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ANALGESICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ANALGESICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ANALGESICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ANALGESICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-OPIOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON-OPIOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ACETAMINOPHEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACETAMINOPHEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ACETAMINOPHEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SALICYLATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SALICYLATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SALICYLATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CODEINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CODEINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FENTANYL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FENTANYL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FENTANYL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HYDROCODONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HYDROCODONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HYDROCODONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MORPHINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MORPHINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MORPHINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OXYCODONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OXYCODONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OXYCODONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAVENOUS (IV) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRAVENOUS (IV) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRAVENOUS (IV) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RECTAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RECTAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RECTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PRESCRIPTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PRESCRIPTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PRESCRIPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ACUTE PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ACUTE PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ACUTE PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INJURY-RELATED PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INJURY-RELATED PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INJURY-RELATED PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL POSTOPERATIVE PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL POSTOPERATIVE PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL POSTOPERATIVE PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHRONIC PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CHRONIC PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHRONIC PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BACK PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BACK PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BACK PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROPATHIC PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEUROPATHIC PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROPATHIC PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANALGESICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANALGESICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. GCC ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. GCC ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 198. GCC ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 199. GCC ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 200. GCC ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. GCC ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 202. GCC ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 203. GCC ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. GCC ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. GCC ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 206. GCC ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 207. GCC ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. G7 ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. G7 ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 234. G7 ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 235. G7 ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 236. G7 ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. G7 ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 238. G7 ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 239. G7 ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. G7 ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 241. G7 ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 242. G7 ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 243. G7 ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. NATO ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. NATO ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 246. NATO ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 247. NATO ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 248. NATO ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. NATO ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 250. NATO ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 251. NATO ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. NATO ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 253. NATO ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 254. NATO ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 255. NATO ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. GLOBAL ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. CANADA ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. CANADA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 271. CANADA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 272. CANADA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 273. CANADA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. CANADA ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 275. CANADA ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 276. CANADA ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 277. CANADA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 278. CANADA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 279. CANADA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 280. CANADA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. MEXICO ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. MEXICO ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 283. MEXICO ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 284. MEXICO ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 285. MEXICO ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. MEXICO ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 287. MEXICO ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 288. MEXICO ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 289. MEXICO ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 290. MEXICO ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 291. MEXICO ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 292. MEXICO ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 293. BRAZIL ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. BRAZIL ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 295. BRAZIL ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 296. BRAZIL ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 297. BRAZIL ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 298. BRAZIL ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 299. BRAZIL ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 300. BRAZIL ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 301. BRAZIL ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 302. BRAZIL ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 303. BRAZIL ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 304. BRAZIL ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED KINGDOM ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED KINGDOM ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED KINGDOM ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED KINGDOM ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED KINGDOM ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED KINGDOM ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED KINGDOM ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED KINGDOM ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED KINGDOM ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED KINGDOM ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED KINGDOM ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED KINGDOM ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 317. GERMANY ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. GERMANY ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 319. GERMANY ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 320. GERMANY ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 321. GERMANY ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 322. GERMANY ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 323. GERMANY ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 324. GERMANY ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 325. GERMANY ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 326. GERMANY ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 327. GERMANY ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 328. GERMANY ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 329. FRANCE ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. FRANCE ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 331. FRANCE ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 332. FRANCE ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 333. FRANCE ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 334. FRANCE ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 335. FRANCE ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 336. FRANCE ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 337. FRANCE ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 338. FRANCE ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 339. FRANCE ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 340. FRANCE ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 341. RUSSIA ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 342. RUSSIA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 343. RUSSIA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 344. RUSSIA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 345. RUSSIA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 346. RUSSIA ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 347. RUSSIA ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 348. RUSSIA ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 349. RUSSIA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 350. RUSSIA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 351. RUSSIA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 352. RUSSIA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 353. ITALY ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 354. ITALY ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 355. ITALY ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 356. ITALY ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 357. ITALY ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 358. ITALY ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 359. ITALY ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 360. ITALY ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 361. ITALY ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 362. ITALY ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 363. ITALY ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 364. ITALY ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 365. SPAIN ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 366. SPAIN ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 367. SPAIN ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 368. SPAIN ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 369. SPAIN ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 370. SPAIN ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 371. SPAIN ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 372. SPAIN ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 373. SPAIN ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 374. SPAIN ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 375. SPAIN ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 376. SPAIN ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 377. CHINA ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 378. CHINA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 379. CHINA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 380. CHINA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 381. CHINA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 382. CHINA ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 383. CHINA ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 384. CHINA ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 385. CHINA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 386. CHINA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 387. CHINA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 388. CHINA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 389. INDIA ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 390. INDIA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 391. INDIA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 392. INDIA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 393. INDIA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 394. INDIA ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 395. INDIA ANALGESICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 396. INDIA ANALGESICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 397. INDIA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 398. INDIA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 399. INDIA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 400. INDIA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MI